AstraZeneca’s Imfinzi demonstrates benefit in combination with antibody

 AstraZeneca’s Imfinzi demonstrates benefit in combination with antibody

AstraZeneca reported on Friday that ‘Imfinzi’ and tremelimumab with chemotherapy demonstrated an overall survival benefit in the ‘POSEIDON’ trial for first-line stage four non-small cell lung cancer, making it the first phase 3 trial to demonstrate an overall survival benefit with tremelimumab.

The AIM-traded firm said Imfinzi plus chemotherapy, meanwhile, demonstrated a progression-free survival benefit, but a trend in overall survival did not achieve statistical significance.

It said POSEIDON was a phase 3 trial of Imfinzi, or durvalumab, plus platinum-based chemotherapy, as well as Imfinzi, tremelimumab and chemotherapy, versus chemotherapy alone, in the first-line treatment of patients with stage four metastatic non-small cell lung cancer.

Positive high-level results from the final analysis of POSEIDON showed the combination of Imfinzi, tremelimumab and chemotherapy demonstrated a statistically significant and clinically…

Read more…

Related post

contact slider
close slider

    Are you a service provider looking for leads or a client looking for a service provider? Drop us a line!